Overview Evaluation of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease Status: Recruiting Trial end date: 2025-05-01 Target enrollment: Participant gender: Summary The primary objective of the study was to evaluate the efficacy and safety of 611 in Chinese adults with moderate to severe COPD. Phase: Phase 2 Details Lead Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.